Why the study?
What is the prevalence and clinical presentation of amiodarone-related hepatic injury in patients receiving amiodarone?
Population
104 patients followed prospectively
Comparison
Amiodarone vs Literature reports (historical control)
Design
Cohort
Authors
Loading...
Supports monitoring for amiodarone hepatotoxicity; leaves open optimal discontinuation thresholds amid competing cardiac risks.
What is the prevalence and clinical presentation of amiodarone-related hepatic injury in patients receiving amiodarone?
Amiodarone therapy is associated with asymptomatic aminotransferase elevation in about 25% of patients and symptomatic hepatitis in 3%, necessitating careful risk-benefit assessment before discontinuation given the competing risk of sudden cardiac death.
Lewis et al. (1989) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: